Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SGPL1 is a pyridoxal phosphate-dependent enzyme that catalyzes the irreversible cleavage of sphingosine-1-phosphate (S1P), a bioactive lipid mediator, into a long-chain fatty aldehyde and phosphoethanolamine. It is the final enzyme in the sphingolipid degradative pathway and serves as the sole exit point for sphingolipid metabolism. SGPL1 plays a crucial role in regulating inflammation, neuronal autophagy, lipid homeostasis, and apoptosis.
SGPL1 catalyzes the irreversible cleavage of sphingosine-1-phosphate (S1P) into a long-chain fatty aldehyde and phosphoethanolamine, thus regulating S1P levels and influencing downstream signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sphingosine-1-phosphate lyase 1 (SGPL1).